Zymeworks Inc. (ZYME) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98985Y1082
Zymeworks Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 105.97 m USD |
| Operating income | -92.55 m USD |
| EBIT | -79.75 m USD |
| Net income | -81.13 m USD |
| Diluted EPS – continuing operations | -1.08 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
More stocks
- Per Aarsleff Holding A/S (PAAL B.CO)
- Ningbo Boway Alloy Material Co Ltd (601137.SS)
- Vermilion Energy Inc (VET.TO)
- Inspire Medical Systems, Inc. (INSP)
- Anhui Honglu Steel Construction Group Co Ltd (002541.SZ)
- Jafron Biomedical Co Ltd (300529.SZ)
- Shanghai Suochen Information Technology Co. Ltd. A (688507.SS)
- LuxNet (4979.TWO)
- Hangzhou Zhongheng Electric Co Ltd (002364.SZ)
- Hebei Huatong Wires and Cables Group Co. Ltd. (605196.SS)
- Aberforth Smaller Companies Trust PLC (ASL.L)
- Atea ASA (ATEA.OL)
Not investment advice. All data without warranty, price as of 27.10.2026. Details in the risk notice.